Department of Radiation Oncology (MAASTRO clinic), GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre+, Postbox 1345, 6201 BH, Maastricht, The Netherlands,
Strahlenther Onkol. 2013 Oct;189(10):834-41. doi: 10.1007/s00066-013-0414-2. Epub 2013 Aug 24.
The purpose of this work was to evaluate outcome after radiotherapy (RT) for laryngeal carcinoma and investigate effects of local relapse on ultimate disease control, including surgical salvage procedures.
In all, 435 patients with laryngeal carcinoma (cT1-cT4a) treated with primary RT were retrospectively analyzed. Uni- and multivariate analyses were performed to identify prognostic factors for local relapse-free survival and overall survival.
Median follow-up was 38 months (range 1-144 months). The cumulative frequency of local recurrence was dependent on T stage: cT1 tumors 10%, cT2 18%, cT3 23%, and cT4 36% (p<0.001). Salvage surgery for local persistent/recurrent disease was performed in 59 of 78 patients (76%). The ultimate local control rates at 5 years (including salvage therapy) were 98, 98, 87, and 68% for cT1, cT2, cT3, and cT4 tumors (p<0.001), respectively. For the patients who developed local recurrence, the 5-year ultimate local control rates were 80, 88, 55, and 26% (p<0.001), respectively. Overall survival at 5 years was 68% for patients without local relapse and 50% for patients experiencing local failure (p<0.001). In univariate analysis, cT stage, cN stage, and tumor volume were statistically significant associated with local relapse-free survival. In multivariate analysis for the cT3-4 tumors, only tumor volume remained statistically significant (HR 1.017, p=0.001) for local relapse-free survival.
Local control rates for cT1-2 laryngeal carcinomas are favorable and in concordance with previous reports and most recurrences are salvaged. For cT3-4 tumors treated with RT alone, initial local control rates are moderate, and in 60% of recurring cases salvage surgery is attempted, with ultimate local control being achieved in only a subset. For voluminous, locally advanced laryngeal tumors, more aggressive treatment modalities should be considered, including upfront laryngectomy or radiochemotherapy.
本研究旨在评估喉癌放疗后的疗效,并探讨局部复发对包括挽救性手术在内的疾病最终控制的影响。
回顾性分析了 435 例接受原发性放疗的喉癌患者(cT1-cT4a)。采用单因素和多因素分析方法,确定局部无复发生存和总生存的预后因素。
中位随访时间为 38 个月(1-144 个月)。局部复发的累积频率与 T 分期有关:cT1 肿瘤为 10%,cT2 为 18%,cT3 为 23%,cT4 为 36%(p<0.001)。78 例局部持续性/复发性疾病患者中有 59 例(76%)接受了挽救性手术。5 年局部控制率(包括挽救性治疗)分别为 cT1、cT2、cT3 和 cT4 肿瘤的 98%、98%、87%和 68%(p<0.001)。对于发生局部复发的患者,5 年最终局部控制率分别为 80%、88%、55%和 26%(p<0.001)。无局部复发患者的 5 年总生存率为 68%,局部失败患者为 50%(p<0.001)。单因素分析显示,T 分期、N 分期和肿瘤体积与局部无复发生存显著相关。多因素分析显示,对于 cT3-4 肿瘤,只有肿瘤体积是局部无复发生存的显著因素(HR 1.017,p=0.001)。
cT1-2 喉癌的局部控制率良好,与既往报道一致,且多数复发可通过挽救性治疗得以控制。对于单独接受放疗的 cT3-4 肿瘤,初始局部控制率中等,60%的复发病例尝试挽救性手术,仅部分患者获得最终局部控制。对于体积较大、局部晚期的喉肿瘤,应考虑更积极的治疗方式,包括 upfront 喉切除术或放化疗。